Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma-Reference-Cited by-同舟云学术

Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma

Published:2021-05 Issue:10 Volume:10 Page:3155-3164
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Mangin Marie‐Alix¹^ORCID,Boespflug Amélie¹²,Maucort Boulch Delphine³,Vacheron Charles‐Hervé³⁴,Carpentier Isabelle⁵,Thomas Luc¹²,Dalle Stéphane¹²

Affiliation:

1. Dermatology Unit Lyon Sud University Hospital Pierre Bénite France

2. Cancer Research Center of Lyon Claude Bernard Lyon–1 UniversityINSERM1052CNRS 5286Centre Leon Berard Lyon France

3. Biostatistics‐Bioinformatics Department Public Health Pole Hospices Civils de Lyon Evolutive biology and biometry laboratory Université Lyon 1CNRS UMR 5558 Villeurbanne France

4. Department of Anesthesia and Resuscitation Lyon Sud University Hospital Pierre Bénite France

5. Pharmacy Unit Lyon Sud University Hospital Pierre Bénite France

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3760

Reference55 articles.

1. Treatment of advanced melanoma in 2020 and beyond;Jenkins RW;J Invest Dermatol,2020

2. Unresectable and Metastatic Melanoma of the Skin: Literature Review of Clinical Trials and Efficacy Endpoints Since 2000

3. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

4. Nivolumab in Previously Untreated Melanoma withoutBRAFMutation

5. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Primary Tumor Characteristics as Biomarkers of Immunotherapy Response in Advanced Melanoma: A Retrospective Cohort Study;Cancers;2024-06-27

2. Is There a Current Role for Combination Chemotherapy or High-Dose Interleukin 2 in Melanoma?;The Cancer Journal;2024-03

3. The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta‐analysis;Pigment Cell & Melanoma Research;2023-12-29

4. Effects of treatment methods on cutaneous melanoma related mortality and all-cause mortality in Texas: TCR-Medicare 2007–2017 database;Cancer Causes & Control;2023-09-13

5. Novel “SMARTer” Clinical Trial Design Improves Odds of Approval and Can Reduce Study Size By 80%: Modeling Use of a ctDNA “Optimizing Diagnostic” for Early Therapy Switching in Immuno-Oncology Trials;2023-02-24